Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.30 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15661135 | 1.00 | CYP3A4 (0.32) | CYP3A4MAPTHPGDALDH1A1PI4KA | |
| SCHEMBL15657817 | 1.00 | CYP3A4 (0.32) | CYP3A4MAPTHPGDALDH1A1PI4KA | |
| SCHEMBL24672314 | 0.89 | CA2 (0.35) | CYP3A4MAPTHPGDALDH1A1PI4KA | |
| SCHEMBL13191781 | 0.89 | CA2 (0.35) | CYP3A4MAPTHPGDALDH1A1PI4KA | |
| SCHEMBL8815319 | 0.89 | CA2 (0.35) | CYP3A4MAPTHPGDALDH1A1PI4KA | |
| SCHEMBL17627244 | 0.89 | CYP3A4 (0.34) | CYP3A4MAPTHPGD | |
| SCHEMBL897160 | 0.89 | CYP3A4 (0.34) | CYP3A4MAPTHPGD | |
| SCHEMBL6825515 | 0.89 | CYP3A4 (0.34) | CYP3A4MAPTHPGD | |
| SCHEMBL15659482 | 0.89 | CYP3A4 (0.34) | CYP3A4MAPTHPGD | |
| SCHEMBL898414 | 0.89 | CYP3A4 (0.34) | CYP3A4MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828406-B2 | Antitumor agent | KINKI UNIVERSITY (JP) | 2017-11-28 | — | — | US | disclosed |
| EP-2716293-B1 | ANTI-TUMOR AGENT | UNIV KINKI (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20140121175-A1 | ANTITUMOR AGENT | KINKI UNIVERSITY (JP) | 2014-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121175-A1 | ANTITUMOR AGENT | UGCG, MAN1B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP3A4 4699/4885MAPT 4633/4885HPGD 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.